黄葵胶囊联合缬沙坦降低贝伐珠单抗肾毒性的临床疗效观察  

Observation of Clinical Efficacy of Huáng KuíCapsules Combined with Valsartan in Reducing the Nephrotoxicity of Bevacizumab

作　　者：邓皇英 邱志敏[1] 吴娟[1] 邓磊 王美鑑[1] DENG Huangying;QIU Zhimin;WU Juan(Jiangxi Cancer Hospital,Nanchang,330029)

机构地区：[1]江西省肿瘤医院,南昌医学院第二附属医院,330029

出　　处：《实用癌症杂志》2024年第9期1524-1528,共5页The Practical Journal of Cancer

基　　金：江西省中医药管理局科技计划课题基金项目(编号:2021B327);江西省肿瘤医院“五层次人才”基金项目(编号:WCDJ2024QH01)。

摘　　要：目的探讨黄葵胶囊、缬沙坦、黄葵胶囊联合缬沙坦对复发性或者晚期肿瘤患者经贝伐珠单抗治疗后出现蛋白尿、高血压的临床疗效。方法选取贝伐珠单抗治疗后出现高血压或者蛋白尿的晚期或者复发肺腺癌、结直肠癌、卵巢癌、宫颈癌及肝细胞癌患者160例,随机分为4组,A组给予安慰剂处理,B组给予黄葵胶囊口服,C组给予缬沙坦胶囊口服,D组给予黄葵胶囊+缬沙坦联合治疗。观察治疗6周、12周后患者血压及尿蛋白情况。结果A组贝伐珠单抗治疗后血压为(145.34±9.87/89.67±9.32)mmHg,经安慰剂治疗12周后血压为(149.08±8.23/92.49±8.92)mmHg;B组贝伐珠单抗治疗后血压为(149.19±8.63/90.71±8.89)mmHg,经黄葵胶囊治疗12周后血压为(150.08±7.73/92.71±7.74)mmHg;C组贝伐珠单抗治疗后血压为(147.78±9.54/91.98±8.01)mmHg,经缬沙坦治疗12周后血压为(118.46±8.13/68.01±6.45)mmHg,P<0.05;D组贝伐珠单抗治疗后血压为(150.65±7.63/89.73±7.84)mmHg,经缬沙坦治疗12周后血压为(108.08±8.76/60.71±7.29)mmHg,P<0.05。A组贝伐珠单抗治疗后尿蛋白为(998.48±65.56)mg/24 h,经安慰剂治疗12周后尿蛋白为(1120.5±39.71)mg/24 h;B组贝伐珠单抗治疗后尿蛋白为(986.53±48.97)mg/24 h,经黄葵胶囊治疗12周后尿蛋白为(260.3±32.51)mg/24 h,P<0.05;C组贝伐珠单抗治疗后尿蛋白为(1020.03±55.91)mg/24 h,经缬沙坦治疗12周后尿蛋白为(265.21±32.73)mg/24 h,P<0.05;D组贝伐珠单抗治疗后血压为(1054±49.78)mg/24 h,经缬沙坦治疗12周后尿蛋白为(59.17±11.52)mg/24 h,P<0.05。结论黄葵胶囊联合缬沙坦能显著降低贝伐珠单抗相关的高血压及蛋白尿,从而降低它的肾毒性。Objective To observe the clinical efficacy of Huangkui Capsules,valsartan,and their combination in the treatment of proteinuria and hypertension in patients with recurrent or advanced tumors following treatment with bevacizumab.Methods 160 patients with late-stage or recurrent lung adenocarcinoma,colorectal cancer,ovarian cancer,cervical cancer,or hepatocellular carcinoma who developed hypertension or proteinuria after bevacizumab treatment were randomly divided into 4 groups.Group A received placebo,Group B received oral Huangkui Capsules,Group C received oral valsartan capsules,and Group D received combined treatment with Huangkui Capsules and valsartan.Blood pressure and urinary protein levels were observed after 6 and 12 weeks of treatment.Results After bevacizumab treatment,the blood pressure in Group A was(145.34±9.87/89.67±9.32)mmHg,and after placebo treatment for 12 weeks,it was(149.08±8.23/92.49±8.92)mmHg.In Group B,the blood pressure after bevacizumab treatment was(149.19±8.63/90.71±8.89)mmHg,and after Huangkui Capsules treatment for 12 weeks,it was(150.08±7.73/92.71±7.74)mmHg.In Group C,the blood pressure after bevacizumab treatment was(147.78±9.54/91.98±8.01)mmHg,and after valsartan treatment for 12 weeks,it was(118.46±8.13/68.01±6.45)mmHg,P<0.05.In Group D,the blood pressure after bevacizumab treatment was(150.65±7.63/89.73±7.84)mmHg,and after valsartan treatment for 12 weeks,it was(108.08±8.76/60.71±7.29)mmHg,P<0.05.After bevacizumab treatment,the urinary protein in Group A was(998.48±65.56)mg/24h,and after placebo treatment for 12 weeks,it was(1120.5±39.71)mg/24h.In Group B,the urinary protein after bevacizumab treatment was(986.53±48.97)mg/24 h,and after Huangkui Capsules treatment for 12 weeks,it was(260.3±32.51)mg/24 h,P<0.05.In Group C,the urinary protein after bevacizumab treatment was(1020.03±55.91)mg/24 h,and after valsartan treatment for 12 weeks,it was(265.21±32.73)mg/24 h,P<0.05.In Group D,the urinary protein after bevacizumab treatment was(1054±49.78)mg/24h,and aft

关 键 词：黄葵胶囊 缬沙坦 贝伐珠单抗 高血压 蛋白尿 

分 类 号：R73-36[医药卫生—肿瘤]